improve patient outcomes and transform the management of acute life threatening neurological conditions by potentially reducing the risks of serious systemic side effects or surgical complications . about edge therapeutics edge therapeutics inc. is a clinical stage biotechnology company that discovers develops and seeks to commercialize novel hospital based therapies capable of transforming treatment paradigms in the management of acute life threatening neurological conditions . our product candidates utilize our proprietary precisa development platform which allows us to create therapeutics that are based on specific physical and chemical properties that enable targeted delivery to the exact site of the injury and provide a controlled and sustained drug release to the affected area . the precisa platform also allows edge to advance new product candidates from concept to preclinical testing in an expedited manner . at edge our primary goal is to save lives around the world by developing therapies for serious unmet medical conditions in the hospital setting . this purpose drives our strategy and our work each and every day . brian leuthner president and ceo latest news edge therapeutics to present at the leerink partners rare disease & immuno oncology roundtable series and participate in additional investor conferences in september read more precisa platform precisa our proprietary programmable biodegradable polymer based development platform enables creation of polymer based therapeutics capable of delivering directly to the site of injury . read more eg 1962 our lead product candidate eg 1962 is a polymer based microparticle containing nimodipine developed with the precisa platform to improve patient outcomes after aneurysmal subarachnoid hemorrhage . read more home about pipeline contact investors news 2016 edge therapeutics inc. all rights reserved .300 connell drive suite 4000 berkeley heights nj 07922info edgetherapeutics.comterms of service